As part of the deal, the company - formerly operating as Comprehensive Neuroscience - will inherit Charles River’s 250-bed, 77,000 square foot Phase I-IIa facility in Tacoma, Washington State, US.
Commenting on the mutually beneficial nature of the agreement, Jack McGovern, CEO of Comprehensive Clinical Development said: “We are thrilled to have the team from Charles River joining the Comprehensive Network.
“We are uniquely aligned with similar cultures, industry experience and business philosophies. What is just as exciting is how complimentary the businesses are in terms of customer mix, service offerings, geographic location and subject populations.”
According to a recently released statement, the deal means the newly combined companies can offer clients 160 years of collective industry experience and the ability to provide “end-to-end ‘turn-key’ clinical development solutions from trial inception to proof of concept.”
In addition, continues the statement, their increased capacity to support clients’ drug development programmes offer a number of benefits, such as: access to leading physicians, specialised pharmacy services, and established experience in conducting radiolabeled studies.
“Joining Comprehensive Clinical Development is a very positive development for our future in the clinical trials industry,” said Charles River general manager, Colleen Hoke.
“Leveraging best practices and the expertise of each firm will provide clear benefits to our clients. The similar cultures and aligned goals of the organisations will facilitate a smooth integration of operations.”
President of Comprehensive Clinical Development, Ali Rodriguez, said the close relationship between management teams prior to the deal being brokered, meant both companies were well positioned to make the most of the new arrangement.
“Having known several members of the Charles river management team for years, I have tremendous respect for their work,” he said.
“We could not have selected a more ideal partner. Our combined capabilities will benefit our clients with a much wider array of clinical development services with the level of commitment they have always received from each company.”